Clinical Trials
Coverage and analysis in clinical trials from the Peptidings newsroom.
Retatrutide Hits 28.3% Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial
Lilly's retatrutide hit 28.3% average weight loss at 12 mg in the pivotal Phase 3 TRIUMPH-1 obesity trial. What the data shows—and what it doesn't yet.
ATTAIN-MAINTAIN: Foundayo Maintains 78–82% of Injectable Weight Loss Over 52 Weeks
Lilly's ATTAIN-MAINTAIN Phase 3b: patients switching from injectable Wegovy or Zepbound to oral Foundayo maintained 78–82% of weight loss over 52 weeks. Nature Medicine.
Wegovy Pill: 21.6% Weight Loss in Early Responders at ECO Day 2
ECO Day 2: Novo's Wegovy pill (oral semaglutide 25 mg) data shows 28.8% of patients qualify as early responders, reaching 21.6% weight loss by Week 64 — narrowing the oral-injectable gap.
89,718 Patients: The Largest Real-World Study of GLP-1 Weight Loss and Comorbidity Risk
Wilding et al. RWE at ECO 2026: 89,718 patients on semaglutide/tirzepatide/liraglutide. ≥15% weight loss = 37% lower OA risk, 69% lower OSA risk. Plus the 50% discontinuation problem.
STEP UP at ECO: Semaglutide 7.2 mg Hits 27.7% Weight Loss in Early Responders
ECO Day 1: Novo's STEP UP data on Wegovy 7.2 mg shows 27.7% weight loss in early responders at Week 72. Plus MRI sub-study confirms 84% of weight loss is fat, not muscle.
Pre-ECO Data: GLP-1s Work in Adults 65+, and the Timing Lines Up with Medicare’s Bridge
Pre-ECO 2026 subgroup data: orforglipron and semaglutide both produce robust weight loss in adults 65+. The evidence base arrives exactly as Medicare's GLP-1 Bridge launches.
An NIH-Funded Nature Paper Maps a Brain Reward Circuit Reached by Oral GLP-1s
NIH-funded Nature paper: oral GLP-1 drugs activate the central amygdala, a deeper brain region than expected. The mechanism behind beyond-weight-loss applications.
The Lancet Publishes the First RCT of Semaglutide for Alcohol Use Disorder
The Lancet publishes SEMALCO: semaglutide reduced heavy drinking days by 13.7 percentage points in adults with alcohol use disorder and obesity. NNT 4.3.
PIONEER TEENS: First Phase 3 of an Oral GLP-1 in Pediatric Type 2 Diabetes
Oral semaglutide pediatric trial PIONEER TEENS reports 0.83% greater HbA1c reduction in adolescents with type 2 diabetes. Novo Nordisk plans H2 2026 label expansion filing.
Retatrutide TRIUMPH-4: Joint Pain Relief Confirmed, a New Safety Signal Emerges
Retatrutide TRIUMPH-4 full data: 71 lbs average weight loss, knee pain reduced up to 75.8%, plus a dysesthesia signal at high doses worth honest scrutiny.
Researchers Scanned 410,000 Reddit Posts for GLP-1 Side Effects. Here’s What Doctors Are Missing.
Penn researchers analyzed 410,000 Reddit posts on GLP-1 drugs and surfaced reproductive and temperature symptoms missing from formal pharmacovigilance. The signal explained.
GLP-1 Drugs and Genetics: Why Response Varies So Much
GLP-1 genetic response: two 2026 studies show why weight loss ranges 6–20% and nausea risk ranges 5–78% on the same drug. The evidence, scoped honestly.
Tirzepatide’s Inventors Just Argued GLP-1 Isn’t Necessary for Weight Loss
Tirzepatide's inventors propose a GIP/glucagon-only obesity drug, arguing GLP-1 activation may not be necessary for weight loss. The class-defying paper, scoped honestly.
A “Gut Reset” Procedure May Prevent Weight Regain After Stopping GLP-1 Drugs—Here Is What the First Controlled Trial Found
First randomized sham-controlled trial shows duodenal mucosal resurfacing maintains 80%+ of weight loss after stopping tirzepatide. Full evidence review.